Aurora Cannabis urges shareholders to reject Curaleaf’s revised hostile offer
Aurora Cannabis told its investors to decline Curaleaf’s updated hostile takeover proposal, saying the deal undervalues the company and would force shareholders to give up a debt‑free balance sheet and future upside. The board, acting on the unanimous advice of an independent special committee, is reviewing alternative strategic options. The offer, which remains open until Dec. 4 2026, provides $1 in cash and 0.4013 Curaleaf shares for each Aurora share, valuing Aurora at $5 per share.
Why it matters
The board’s recommendation means shareholders should not tender their shares, keeping the company free to pursue potentially higher‑value alternatives. Analysts at TipRanks maintain a Hold rating with a C$7.00 price target, reflecting the view that the bid does not improve Aurora’s valuation.
Key facts
- 1The hostile bid stays open until Dec. 4 2026. prnewswire.com
- 2Aurora’s board, following the unanimous advice of an independent special committee, recommends shareholders reject the offer. prnewswire.com
- 3CEO Miguel Martin said Aurora is debt‑free and has a strong cash position. prnewswire.com
- 4The revised offer values Aurora at $5 per share, consisting of $1 cash and 0.4013 Curaleaf shares. seekingalpha.com
- 5TipRanks rates ACB as Hold with a C$7.00 price target. tipranks.com
- 6Aurora’s market capitalization is C$416.3 million. tipranks.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.